Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionStrategies for early detection of resectable pancreatic cancerChemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancyPerioperative Therapy for Surgically Resectable Pancreatic AdenocarcinomahENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPancreatic cancer treatment and research: an international expert panel discussion.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Biomarkers in pancreatic adenocarcinoma: current perspectivesGenetic factors affecting patient responses to pancreatic cancer treatmentFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerNew challenges in perioperative management of pancreatic cancerHuman concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.Fluoropyrimidine ActivityImmunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.Equilibrative nucleoside transporters-A review.Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cellsSurvivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.Evolution of systemic therapy for advanced pancreatic cancer.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.Understanding Drug Resistance in Breast Cancer with Mathematical OncologyCellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaPersonalising pancreas cancer treatment: When tissue is the issue.Pancreatic cancer-improved care achievableTranslational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Therapeutic options for the management of pancreatic cancer.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyAdjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.Pancreatic cancer genomics: where can the science take us?S-1 in the treatment of pancreatic cancer.
P2860
Q24273350-5FDD65CD-C8FF-4BB5-ACF6-7EA948B3499EQ24564006-9D67C014-C51F-4F66-94D8-4C01668B0EA4Q26746031-F05033C6-533C-4EA3-B830-C2D543472A12Q26752368-0493F17B-F56E-4C72-875C-89B0A19CF4C1Q26767120-9CBD1401-514B-4C8F-BAA9-AD6AB99062FCQ26801411-BC6A1B69-2561-4079-83D0-D7BB8C339EA7Q26862139-C577F3B4-160A-447B-B91E-95942FBB8974Q27004292-D2FACEBD-0519-4436-B087-F54D69879F2DQ27021716-2789083C-5E6A-4503-A1AC-5A7AAC330BBFQ27690868-E0A404B9-248D-40E8-970D-C1C1703DE911Q28066268-40B2392D-5842-44D4-8ECD-B02715AABF1FQ28072309-0942BF05-D747-45CE-A519-0C23B2265ED6Q28075293-A31D21BD-2A03-4CD0-B8AE-B20CDDFD1C48Q28075540-81496B90-3D4B-4C2C-B0C3-A6BD38B66E23Q28082422-F23F6134-AFBA-410E-814F-166DB0535787Q28486221-554ADED4-7833-4CD9-80E6-DDBD313CF9BFQ29883401-DA47C042-FA92-4A93-9CCC-1FB2AB43D323Q30238470-7F6E1BD1-A0E0-4F18-AFB6-41C4DAA3887AQ30244329-9C5194F7-CBE0-4C47-8D78-FE35DBFE3AD4Q30405605-6AD49BCD-96AA-4E4F-A101-C5286609348EQ33418045-C85F7895-AA4E-409B-991C-075F83A24244Q33557413-EE595E2E-3C89-4C6B-A59C-AF9CBC5BF48EQ33575608-CC64EF07-CD02-4B20-8E86-DD45C81B18F4Q33630872-2E4AB3AA-9448-4EDD-9A74-63B08376BB50Q33690336-ECCE00BF-6F17-4259-9DA0-4AF9258B8A4AQ33711106-1EFC43B7-0203-4B10-AED0-15B778DF3043Q33727842-2FD32071-E852-41C2-A97F-9E6157C97CA2Q33751227-84439D4C-C479-4B5C-986A-5DBACA25C53DQ33801384-AF2FACB3-5C4B-4808-812E-FCCD338A0EA9Q34036659-5151CD6C-845D-4CB3-85A2-FE3E50F374A9Q34067863-8F4B443F-1223-4FED-BDC5-A471C7486005Q34093776-DA97DD92-A197-4288-BE5C-37B6DFD40AE9Q34127857-DF20B21F-5AAB-4F97-9A72-CE0A08C0FFE8Q34177223-17AFA35B-45A1-4490-91D1-305379BFD118Q34234101-A5B100D4-0021-4251-B86A-7497F8A1D0B9Q34254837-4C342A31-6ED0-4237-B973-56994C23DCEAQ34283650-768D0078-116E-4ED0-B80D-B71F4C705D18Q34334926-E9705071-829B-40CC-8F85-9D2F1F984564Q34447458-B01AF7B4-6ACA-43C0-9F66-DCDE1882C0C3Q34467156-8F5CAFAB-FFC9-4552-8662-FC4E34FC9D34
P2860
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@ast
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@en
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@nl
type
label
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@ast
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@en
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@nl
altLabel
Human equilibrative nucleoside ...... atients with pancreatic cancer
@en
prefLabel
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@ast
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@en
Human equilibrative nucleoside ...... tients with pancreatic cancer.
@nl
P2093
P3181
P1433
P1476
Human equilibrative nucleoside ...... atients with pancreatic cancer
@en
P2093
A Bowen Benson
Carol E Cass
Hany Elsaleh
James J Farrell
John Macdonald
Miguel Garcia
Raymond Lai
Ross Abrams
William F Regine
P304
P3181
P356
10.1053/J.GASTRO.2008.09.067
P407
P577
2008-10-07T00:00:00Z